Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood filter for sepsis: does it remove Life-Saving antibiotics?

NCT ID NCT06602245

Knowledge-focused Sponsor: Efferon JSC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a blood-filtering device called Efferon LPS removes antibiotics from the blood of people with sepsis. Sepsis is a severe infection that can lead to organ failure, and doctors sometimes use filters to clean the blood. The study included 30 patients and measured how much antibiotic was cleared by the filter. The goal was to see if the filter might accidentally reduce antibiotic levels, which could make treatment less effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Efferon LPS hemoperfusion device
What this could lead to
If successful, this could help doctors understand how to safely use the Efferon LPS device without reducing antibiotic effectiveness in sepsis patients.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply to all patients. It only measures drug clearance, not patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Oct 2024

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The expected number of study subjects is 30 adult patients with sepsis and/or septic shock (presumably of Gramnegative aetiology and any localisation). It is planned to recruit : * 10 patients receiving meropenem * 10 patients receiving vancomycin * 10 patients receiving linezolid. Patients may receive more than one of these antibiotics at the same time, in which case they will be included in several subpopulations of the study.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient weight greater than 40 kg. * Diagnosis of sepsis and/or septic shock according to CEPSIS-3 criteria (2016), presumed (at time of enrolment) to be of Gram-negative aetiology, requiring, in the opinion of the investigator, isolated lipopolysaccharide hemoperfusion. Exclusion Criteria: * Failure to obtain informed consent from the patient, family member or legal representative. * Any patient condition requiring other methods of renal replacement therapy (e.g. hemodialysis, hemofiltration, hemodiafiltration). * Pregnancy, breastfeeding period. * General contraindications to extracorporeal treatments. * Any other condition that, in the opinion of the investigator, would prevent the patient from being a suitable candidate for inclusion in the study (e.g. terminal chronic disease). * Development of an adverse event, including a serious adverse event; individual intolerance to the investigational product, hypersensitivity to the components of the product due to which further participation in the study is not possible. * Continued participation in the study is not, in the opinion of the investigator, in the best interests of the patient\'s health. * The patient, in the opinion of the investigator, fails to comply with the requirements of the study procedures. * The presence of protocol deviations that, in the opinion of the Sponsor and the investigator, require withdrawal of the participant from the study. * A positive pregnancy test result at any time during the study. * Use of any other methods of renal replacement therapy and extracorporeal hemocorrection during isolated hemoperfusion with the Efferon LPS device.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis Septic shock

Contacts and locations

Locations

  • N. V. Sklifosovsky Moscow Research Institute of Emergency

    Moscow, Russia

  • N.I. Pirogov City Clinical Hospital No. 1

    Moscow, Russia

  • Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko

    Nizhny Novgorod, Russia

  • Perm regional clinical hospital

    Perm, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.